Myriad Genetics (MYGN) Stock Forecast & Price Target

$13.36 +0.19 (+1.44%)

(As of 12/20/2024 05:16 PM ET)

Myriad Genetics - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Hold

Based on 12 Analyst Ratings

Sell
3

Hold
6

Buy
3

Based on 12 Wall Street analysts who have issued ratings for Myriad Genetics in the last 12 months, the stock has a consensus rating of "Hold." Out of the 12 analysts, 3 have given a sell rating, 6 have given a hold rating, and 3 have given a buy rating for MYGN.

Consensus Price Target

$24.27
81.68% Upside

According to the 12 analysts' twelve-month price targets for Myriad Genetics, the average price target is $24.27. The highest price target for MYGN is $35.00, while the lowest price target for MYGN is $13.00. The average price target represents a forecasted upside of 81.68% from the current price of $13.36.

Get the Latest News and Ratings for MYGN and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Myriad Genetics and its competitors.

MYGN Analyst Ratings Over Time

Type	Current Forecast 12/23/23 to 12/22/24	1 Month Ago 11/23/23 to 11/22/24	3 Months Ago 9/24/23 to 9/23/24	1 Year Ago 12/23/22 to 12/23/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	3 Buy rating(s)	7 Buy rating(s)	7 Buy rating(s)	4 Buy rating(s)
Hold	6 Hold rating(s)	3 Hold rating(s)	3 Hold rating(s)	3 Hold rating(s)
Sell	3 Sell rating(s)	2 Sell rating(s)	2 Sell rating(s)	1 Sell rating(s)
Consensus Price Target	$24.27	$27.36	$28.91	$23.38
Forecasted Upside	81.68% Upside	76.65% Upside	7.35% Upside	15.15% Upside
Consensus Rating	Hold	Hold	Hold	Hold

Vladimir Lenin was right… (Ad)

The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold $3 billion of Amazon… it’s why Nvidia’s CEO just sold $713 million... and it’s why Zuckerberg just sold $1.3 billion in Meta stock. The financial establishment doesn’t want you to know about this… but a controversial new documentary just pulled back the curtain and exposed what’s really going on. It’s called The Final Frontier.

Including the name of the #1 company to buy.

MYGN Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

MYGN Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Myriad Genetics Stock vs. The Competition

Type	Myriad Genetics	Medical Companies	S&P 500
Consensus Rating Score	2.00	2.81	2.51
Consensus Rating	Hold	Moderate Buy	Moderate Buy
Predicted Upside	81.68% Upside	25,828.59% Upside	14.53% Upside
News Sentiment Rating	Neutral News See Recent MYGN News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
12/13/2024	Bank of America 3 of 5 stars		Lower Target	Underperform ➝ Underperform	$15.00 ➝ $13.00	-7.34%
12/10/2024	UBS Group 4 of 5 stars	L. Li Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Neutral	$18.00	+20.97%
12/9/2024	Leerink Partnrs 5 of 5 stars	P. Souda Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
12/9/2024	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Outperform ➝ Market Perform	$30.00 ➝ $21.00	+38.80%
11/18/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Equal Weight ➝ Equal Weight	$32.00 ➝ $21.00	+37.70%
11/11/2024	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral ➝ Neutral	$30.00 ➝ $24.00	+37.85%
Get the Latest News and Ratings for MYGN and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Myriad Genetics and its competitors with MarketBeat's FREE daily newsletter.
8/27/2024	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	B. Couillard Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$35.00	+27.27%
8/13/2024	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	S. Nam Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Sector Outperform ➝ Sector Outperform	$29.00 ➝ $34.00	+21.65%
8/7/2024	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Hold ➝ Hold	$28.00 ➝ $30.00	+12.61%
8/7/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Underweight ➝ Underweight	$17.00 ➝ $20.00	-23.95%
6/3/2024	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Hold ➝ Underperform	$25.00 ➝ $20.00	-10.11%
1/29/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$28.00 ➝ $31.00	+38.89%
12/14/2023	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$23.00	+10.15%
12/13/2023	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform	$28.00	+46.98%
3/6/2023	Stephens Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Equal Weight	$17.00 ➝ $24.00	+3.18%
3/3/2023	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform	$25.00 ➝ $27.00	+17.39%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 03:44 AM ET.

MYGN Forecast - Frequently Asked Questions

: According to the research reports of 12 Wall Street equities research analysts, the average twelve-month stock price forecast for Myriad Genetics is $24.27, with a high forecast of $35.00 and a low forecast of $13.00.
: 12 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Myriad Genetics in the last year. There are currently 3 sell ratings, 6 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" MYGN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MYGN, but not buy additional shares or sell existing shares.
: According to analysts, Myriad Genetics's stock has a predicted upside of 81.68% based on their 12-month stock forecasts.
: Over the previous 90 days, Myriad Genetics's stock had 2 downgrades by analysts.
: Myriad Genetics has been rated by research analysts at Bank of America, Leerink Partners, Leerink Partnrs, Morgan Stanley, Piper Sandler, and UBS Group in the past 90 days.
: Analysts like Myriad Genetics less than other "medical" companies. The consensus rating for Myriad Genetics is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how MYGN compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

Why Buffett, Griffin and 100 members of Congress are Piling into this One Investment (Ad)

This isn't just another investment. It might be the last retirement stock you'll ever need. But this window of opportunity is closing fast.

Click here for the ticker >>>

This page (NASDAQ:MYGN) was last updated on 12/22/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Myriad Genetics (MYGN) Stock Forecast & Price Target